CYP2C19 converts the tricyclic antidepressant imipramine to its active metabolite desipramine, which is subsequently inactivated by CYP2D6. The novel CYP2C19*17 allele causes ultrarapid metabolism of CYP2C19 substrates. We genotyped 178 depressed patients on imipramine for CYP2C19*17, and measured steady-state imipramine and desipramine plasma concentrations. Mean dose-corrected imipramine plasma concentration was significantly dependent on CYP2C19 genotype (Kruskal-Wallis test, P ¼ 0.01), with circa 30% lower levels in CYP2C19*17/*17 individuals compared with CYP2C19*1/*1 (wild-type) patients. The mean dosecorrected imipramine þ desipramine plasma concentrations and imipramine/desipramine ratios were not significantly different between genotype subgroups (Kruskal-Wallis tests, PX0.12). In a multivariate analysis, we found a significant, but limited effect (P ¼ 0.035, Z 2 ¼ 0.031) of the CYP2C19*17 genotype on imipramine þ desipramine concentrations. Although the CYP2C19*17 allele is associated with a significantly increased metabolism of imipramine, CYP2C19*17 genotyping will, in our view, not importantly contribute to dose management of patients on imipramine therapy guided by imipramine þ desipramine plasma concentrations.
Introduction
Major depression is a serious medical illness affecting over 340 million people worldwide. 1 Pharmacotherapy using tricyclic antidepressants, including imipramine, clomipramine, amitriptyline and nortriptyline, 2 has been an essential constituent of antidepressive treatment for over 30 years. 3 The typical tricyclic antidepressant imipramine is metabolized by cytochrome P450 enzymes. CYP2C19 primarily converts imipramine to its active metabolite desipramine, which is subsequently hydroxylated by CYP2D6, generating inactive 2-hydroxydesipramine. [4] [5] [6] In daily practice, the sum of the plasma concentrations of parent imipramine and active metabolite desipramine is often used to guide imipramine therapy. 7 There are large interindividual differences in CYP2C19 and CYP2D6 activity (ranging from completely absent to normal and distinctly increased), mainly because of polymorphisms in the corresponding genes.
Carriers of two CYP2C19 wild-type alleles are expected to be extensive metabolizers, heterozygous carriers to be intermediate metabolizers and carriers of two CYP2C19 null alleles to be poor metabolizers (1-6% of Caucasians). 8 The common CYP2C19*2 null allele 10, 11 accounts for the vast majority of poor metabolizer phenotypes in Caucasians (allele frequency in healthy Dutch volunteers, 13% 12 ); in addition, the inactive CYP2C19*3 allele is predominantly found in Asians. 11, 13 These genetic polymorphisms may affect steady-state imipramine plasma concentrations and molar imipramine/desipramine ratios. Indeed, using standard drug doses, higher mean imipramine plasma concentrations and imipramine/desipramine ratios were previously found in patients with two CYP2C19 null alleles compared with patients with two CYP2C19 wild-type alleles. 14, 15 This may result in more effective therapy, but also in side effects induced by unexpectedly high drug levels in poor metabolizers. As different effects have been described for imipramine vs desipramine (with a smaller distribution volume, a lower erythrocyte/plasma ratio and a 2.6-fold lower case fatality rate for imipramine 16 ), a higher parent/daughter ratio may also lead to paradoxical outcomes, such as the requirement for higher therapeutic plasma concentrations.
Recently, Sim et al. 17 described the novel CYP2C19 gene variant CYP2C19*17, which has an allele frequency of 18-27% in different European populations. [18] [19] [20] It is associated with increased gene transcription and thus faster metabolism of CYP2C19 substrates mephenytoin, omeprazole, voriconazole and escitalopram. 17, 19, 21, 22 In contrast to defective CYP2C19*2 and *3 alleles, CYP2C19*17 may thus be associated with ultrarapid metabolism and, therefore, therapeutic failure upon proton pump inhibitor, antifungal or antidepressant treatment. 17, 23 The primary aim of this study was to investigate whether the CYP2C19*17 genotype is also correlated with altered imipramine pharmacokinetics. In order to do so, we assessed the novel CYP2C19 polymorphism *17 and measured steady-state imipramine and desipramine plasma concentrations in a large group (n ¼ 178) of depressed patients on imipramine, taking into account CYP2C19*2 and CYP2D6 genotype (*3, *4, *5, *6, *9, *10, *41, and gene duplication).
Materials and methods

Patients
A total of 178 psychiatric patients aged between 18 and 65 years, with a Diagnostic and Statistical Manual, 4th edition diagnosis of depressive disorder and a score of X17 on the Hamilton Rating Scale for Depression, were recruited from a retrospective single-center study conducted at the Department of Psychiatry of the Erasmus MC in Rotterdam, The Netherlands. 24 Ethnicity was not explicitly recorded, but the vast majority (495%) of patients were Caucasians. The Ethics Committee of the Erasmus MC approved the protocol, the study was carried out according to the principles of the Declaration of Helsinki, and patients provided written informed consent.
Clinical study
Imipramine (Tofranil, Ciba-Geigy BV, Arnhem, The Netherlands) was given orally once daily at 2200 hours, at a dose of 25-900 mg per day. Treatment was started by administering 75 mg imipramine for 2 days, followed by 150 mg imipramine for 5 days and a further increase in dose where necessary. Blood samples were taken by venepuncture between 0730 and 0900 hours on the day after medication. Imipramine and desipramine plasma concentrations were measured at the Department of Hospital Pharmacy on a regular basis, according to a routine procedure by using HPLC with ultraviolet detection at 220 nm as described. 24 The imipramine dose was adjusted based on a predefined imipramine þ desipramine target plasma concentration of 200-300 mg l À1 . 7 Given the elimination half-life values of 8-20 and 12-76 h for imipramine and desipramine, 25 respectively, treatment with an unchanged dose of imipramine for at least 12 consecutive days (4 Â 3 days, or four elimination half-lives for the compound and phenotype with longest elimination half-life) was chosen as to define the steady state. For each individual patient, a median value of all imipramine and imipramine þ desipramine plasma levels at steady state, and all molar imipramine/desipramine ratios at steady state was calculated, using molecular masses of 280.4 and 266.3 g mol À1 for imipramine and desipramine, respectively. 24, 26 The median individual steady-state values were then used for all (sub)group analyses, that is, medians were used for each individual, whereas mean values were only used for observations applying to (sub)groups of patients.
Genotyping
Genotyping was performed at the Department of Clinical Chemistry. First, genomic DNA was isolated from 200 ml of EDTA-treated whole blood for each patient, using a MagNA Pure LC (Roche Diagnostics GmbH, Mannheim, Germany). Genotyping of the CYP2C19 single-nucleotide polymorphisms, -3402C4T and -806C4T, corresponding to the *17 allele, 11, 17 was performed using TaqMan allelic discrimination assays on an ABI Prism 7000 sequence detection system (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Polymerase chain reactions were performed using unlabeled target-specific primers, allele-specific TaqMan minor groove binder-DNA probes (labeled with the fluorescent dyes VIC and FAM for the wild-type and variant allele, respectively), and TaqMan (with the alleles in brackets, the wild-type nucleotide corresponding to the VIC probe in bold, and the variant nucleotide corresponding to the FAM probe underlined). The thermal profile consisted of an initial incubation at 50 1C for 2 min, denaturation at 95 1C for 10 min, followed by 50 cycles of denaturation at 92 1C for 15 s, and annealing and extension at 60 1C for 1 min. Genotypes were scored by measuring allele-specific fluorescence using SDS software for allelic discrimination (Applied Biosystems). CYP2C19*2 and CYP2D6 *1-*6, *9, *10 and *41 genotypes, and CYP2D6 gene duplication, were assessed by PCR-restriction fragment length polymorphism analysis and conventional PCR as previously described.
24 CYP2D6 alleles were designated according to the Human Cytochrome P450 Allele Nomenclature Committee website.
11 Individuals with two CYP2D6 null alleles (*3, *4, *5 or *6; n ¼ 9, corresponding to 5% of the patient group) and subjects showing gene duplication resulting in three or more active alleles (n ¼ 11, 6%) were classified as CYP2D6 poor and ultrarapid metabolizers, respectively. All genotyping assays were validated by sequencing.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism version 2.01 (GraphPad Software, Inc., San Diego, CA, USA) and SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). In order to discover possible differences between subgroups, data were analyzed using Kruskal-Wallis and MannWhitney nonparametric ANOVA. Reported P values are two-tailed.
Results
Imipramine and desipramine plasma concentrations and imipramine/desipramine ratios A total of 726 steady-state samples (mean 4.1 samples, up till 15 samples per patient) were included in the analysis. For each individual patient, a median value of all imipramine plasma levels, all imipramine þ desipramine plasma concentrations and all molar imipramine/desipramine ratios was determined, blinded for genotype. The overall (n ¼ 178) descriptive statistics for these measures are given in Table 1 . Even though imipramine dosing was guided by therapeutic drug monitoring, 53 patients (30%) showed steady-state imipramine þ desipramine levels outside the predefined target range of 200-300 mg l À1 . 7 Thirty-four patients (19%) showed steady-state imipramine þ desipramine plasma concentrations below the predefined range, and 19 patients (11%) had imipramine þ desipramine levels above this range.
CYP2C19 genotyping
We identified 11 out of 178 patients (6%) as CYP2C19*17/ *17, and 65 patients (37%) as heterozygous carriers of CYP2C19*17, yielding a total *17 allele frequency of 24%; heterozygous *17 carriers included 52 subjects (29%) genotyped as CYP2C19*1/*17. Five patients (3%) carried two CYP2C19 null alleles (*2/*2; predicted phenotype, poor metabolizer), 32 patients (18%) were carriers of one CYP2C19 null allele and one CYP2C19 wild-type allele (*1/ *2; predicted phenotype, intermediate metabolizer), and 13 patients (7%) were carriers of one CYP2C19*2 and one CYP2C19*17 allele (*2/*17), yielding a *2 allele frequency of 15% (as anticipated 12 ). The remaining 65 patients (37%) were characterized as wild-type (CYP2C19*1/*1; predicted phenotype: extensive metabolizer).
Effect of the CYP2C19*17 allele The CYP2C19 genotype subgroups (*2/*2, *1/*2, *2/*17, *1/ *1, *1/*17 and *17/*17) showed a significant difference in mean dose-corrected imipramine plasma concentration (Kruskal-Wallis test, P ¼ 0.01). Patients carrying one or more CYP2C19*17 alleles showed lower imipramine plasma levels compared with those without *17 alleles. The mean dosecorrected imipramine concentrations were 13% lower for heterozygous CYP2C19*17 carriers (Mann-Whitney test, P ¼ 0.16) and 28% lower for CYP2C19*17/*17 individuals (P ¼ 0.041), compared with wild-type subjects. Patients with CYP2C19*17/*17 or *1/*17 genotype had circa twofold lower dose-corrected imipramine levels than *2/*2 or *1/*2 individuals (Pp0.02). Although patients with CYP2C19*2/ *17 genotype showed 16% higher dose-corrected imipramine plasma concentrations than *1/*1 subjects, the difference was not significant (P ¼ 0.70; Figure 1a and Table 2 ). Similar results were obtained if the data were corrected for body weight as well (Kruskal-Wallis test, P ¼ 0.01).
In order to assess the effect of the CYP2C19*17 allele without influence from the most common CYP2C19 null allele or aberrant CYP2D6 genotypes, all subjects carrying one or more CYP2C19*2 alleles, and all CYP2D6 poor and ultrarapid metabolizers (based on CYP2D6 genotyping as described above) were excluded from the analysis. Again, the CYP2C19 genotype subgroups (*1/*1, *1/*17 and *17/*17; n ¼ 115) showed a significant difference in mean dose-corrected imipramine plasma concentration (KruskalWallis test, P ¼ 0.045), with 18 and 30% lower imipramine concentrations for heterozygous CYP2C19*17 carriers (Mann-Whitney test, P ¼ 0.0497) and CYP2C19*17/*17 Table 2 ).
The mean imipramine þ desipramine plasma concentration per dose unit did not differ significantly between the CYP2C19 genotype subgroups (Kruskal-Wallis test, P ¼ 0.29; Table 3 ). The same was true if all subjects with one or more CYP2C19*2 alleles were excluded from the analysis (KruskalWallis test, P ¼ 0.29 for 128 remaining subjects), and when CYP2D6 poor and ultrarapid metabolizers were excluded as well (Kruskal-Wallis test, P ¼ 0.20 for the 115 remaining subjects; Table 3 ). In addition, the mean molar imipramine/ desipramine ratios were not significantly different between the CYP2C19 genotype subgroups, using either of the above-mentioned approaches (Kruskal-Wallis tests, PX0.12; Table 3 ).
Univariate and multivariate analysis
Variables sex, body weight, number of CYP2C19*17 alleles and number of active CYP2D6 alleles (semiquantitative functional gene dose as previously described 3, 24 ) were considered to be of potential interest for the prediction of mean dose-corrected imipramine plasma level, imipramine þ desipramine plasma concentration and molar imipramine/ desipramine ratio using a linear regression model. When univariately analyzed, all variables significantly contributed to the prediction of imipramine plasma concentration per dose unit (Pp0.026). Sex, weight and semiquantitative functional CYP2D6 gene dose were significant covariates for the prediction of imipramine þ desipramine plasma concentration per dose unit (Pp0.029), whereas the number of CYP2C19*17 alleles did not significantly contribute (P ¼ 0.064). The number of active CYP2D6 alleles significantly added to the prediction of the imipramine/desipramine ratio (Po0.001), whereas the other variables did not (PX0.29).
The multivariate linear regression model showed that the number of CYP2C19*17 alleles (P ¼ 0.01, Z 2 ¼ 0.046) and the number of active CYP2D6 alleles (Po0.001, Z 2 ¼ 0.088) were the only factors that significantly contributed to the prediction of dose-corrected imipramine plasma level. Interestingly (and perhaps surprisingly), in the multivariate model, both the semiquantitative functional CYP2D6 gene dose (Po0.001, Z 2 ¼ 0.268) and the number of CYP2C19*17 alleles (P ¼ 0.035, Z 2 ¼ 0.031) significantly added to the prediction of dose-corrected imipramine þ desipramine plasma concentration (whereas sex and body weight did not, at PX0.11).
Discussion
The typical tricyclic antidepressant imipramine is metabolized by the polymorphic enzymes CYP2C19 and CYP2D6. [4] [5] [6] Prior knowledge of the potential individual drug-metabolizing capacity, provided by CYP2C19 and CYP2D6 genotyping, may predict optimal imipramine dosing at an early point, reducing the number of patients with imipramine þ desipramine plasma levels outside the predefined therapeutic range 7 during the first stages of treatment. Recently, the novel common CYP2C19*17 allele was associated with increased gene transcription and faster metabolism of CYP2C19 substrates. 17, 19, 21, 22 It was shown that healthy CYP2C19*17/*17 individuals experience a decrease of 52% in systemic omeprazole exposure as compared with healthy wild-type subjects, 21 and it was postulated that *17/*17 individuals would require a 50% increase in escitalopram dose in order to achieve drug exposures similar to *1/*1 subjects. 19 The primary aim of this study was to explore whether the presence of the CYP2C19*17 allele is also correlated with altered imipramine metabolism. A total of 178 depressed psychiatric patients treated with imipramine were dosetitrated towards an imipramine þ desipramine target level, and dose-corrected drug plasma concentrations were calculated, assuming linear pharmacokinetics as previously described. 24 We show that the CYP2C19*17 allele was significantly associated with decreased imipramine levels in this large group of patients. In line with this, our present multivariate linear regression model showed that the number of CYP2C19*17 alleles significantly contributed to the prediction of imipramine plasma concentration. Imipramine plasma concentrations in relation to CYP2C19 genotype, with all subjects carrying CYP2C19*2 alleles, and all CYP2D6 poor and ultrarapid metabolizers excluded from the analysis (remaining patients, n ¼ 115; Kruskal-Wallis test, P ¼ 0.045). Shown are median concentrations per drug dose unit at steady state (one data point per subject), per CYP2C19 genotype as indicated. The horizontal lines represent subgroup means. Significant differences vs CYP2C19 wild-type (*1/*1) are indicated (Mann-Whitney analyses, Po0.05). For further details, see Table 2 . Shown are mean ( ± s.d.) molar imipramine/desipramine ratios at steady state in relation to CYP2C19 genotype. e CYP2C19*17 genotype, with all subjects carrying CYP2C19*2 alleles excluded, and all CYP2D6 poor and ultrarapid metabolizers excluded from the analysis (remaining subjects, n ¼ 115). All values referring to the wild-type subgroup are underlined. In addition, patients carrying the CYP2C19*17 allele showed slightly lower mean dose-corrected imipramine þ desipramine plasma levels. In the multivariate linear regression model, there was a small, but significant contribution of the number of CYP2C19*17 alleles to the prediction of imipramine þ desipramine plasma concentration. Despite these findings, there were no significant differences in dose-corrected imipramine þ desipramine plasma levels between the CYP2C19 *2/*2, *1/*2, *2/*17, *1/*1, *1/*17 and *17/*17 subgroups. Although patients with the CYP2C19*17 allele showed slightly lower molar imipramine/desipramine ratios, there were no significant differences in these ratios between the CYP2C19 genotype subgroups either, and there was no effect of the CYP2C19*17 polymorphism in our regression analysis. The somewhat puzzling finding, that imipramine plasma levels were, but imipramine þ desipramine concentrations and imipramine/desipramine ratios were not, significantly different between CYP2C19 subgroups, suggests a prominent role for desipramine conversion. Next to CYP2D6 genotype, 24 other, unknown factors may be importantly involved in desipramine metabolism, which may influence imipramine þ desipramine plasma levels and imipramine/desipramine ratios to a greater extent than imipramine concentrations alone.
Another interesting point is the metabolic capacity of the 13 subjects with genotype CYP2C19*2/*17. One could speculate that the overall CYP2C19 activity of a CYP2C19*2/*17 subject would be comparable to wild type, because of the presence of one deficient and one highactivity allele. Although our data seem to fit this hypothesis, it was previously found that the CYP2C19*17 allele is of quantitatively less importance than the defective CYP2C19*2 and *3 alleles in the metabolism of omeprazole, 21 escitalopram 19 and sertraline. 27 Patients with a combined CYP2C19*17/defective genotype showed higher dose-corrected escitalopram serum concentrations, 19 and higher dose-adjusted serum concentrations of sertraline and its primary metabolite N-desmethyl sertraline, 27 as compared with CYP2C19*1/*1 patients. Interestingly, it was recently shown that the presence of the CYP2C19*17 allele is significantly associated with better platelet response to clopidogrel, without significant interaction with the CYP2C19*2 allele, suggesting that the CYP2C19*17 allele influences platelet response independently from the *2 allele. 28 Theoretically, one might expect that CYP2C19*17 carriers would need to receive different doses of imipramine as compared with wild-type subjects. However, we demonstrate that the effect of this allele is limited, and that, therefore, it seems to be of no significance for clinically relevant imipramine þ desipramine levels. We thus conclude that there is no need to perform CYP2C19*17 genotyping for clinical practice. Yet, CYP2C19*17 genotyping may prove valuable in complex subjects, for whom it may be used to establish their full metabolic capacity. Possibly, the CYP2C19*17 allele might be a contributing factor behind individual cases of therapeutic failure, as previously suggested for other CYP2C19 substrates. 21, 29 In this study, the efficacy of imipramine treatment was not determined. Therapeutic efficacy is difficult to assess in these depressed patients, and it is believed to be directly related to imipramine þ desipramine plasma concentrations, with a 67% response rate within the therapeutic range vs 39% outside this range. 30 Therapy in our hospital is thus based on plasma concentrations, which is the reason we used these as the outcome measure for therapy efficacy. Albeit complicated, it would, obviously, be interesting to obtain data regarding the resulting Diagnostic and Statistical Manual and/or Hamilton scores upon antidepressant pharmacotherapy in relation to genotype in future studies.
As noted in the Introduction, different effects have been described for parent imipramine compared with its active daughter desipramine. 16 Whereas the CYP2C19*17 allele does not significantly decrease the summed concentration of imipramine and desipramine, enhanced CYP2C19 enzyme activity corresponding to the presence of CYP2C19*17 might thus still modify the clinical outcome by influencing the imipramine plasma level alone.
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